Clinical trial
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
NCT00314288 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00314288 |
|---|---|
| Title | Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia |
| Official title | A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease, Dyskinesia |
| Intervention type | Drug |
| Interventions | Sarizotan HCl |
| Enrollment | 360 |
| Start date | Jul 1, 2002 |
| Completion | Jul 1, 2003 |
| First posted | Apr 13, 2006 |
| Last update posted | Jan 23, 2017 |
| Countries | Belgium, Bulgaria, Canada, France, Germany, Hungary, Portugal, Romania, South Africa, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: